Comparison of infectious complications with BCMA-directed therapies in multiple myeloma - Top-Institutions - MDSpire

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

  • By

  • Karthik Nath

  • Tala Shekarkhand

  • David Nemirovsky

  • Andriy Derkach

  • Bruno Almeida Costa

  • Noriko Nishimura

  • Tasmin Farzana

  • Colin Rueda

  • David J. Chung

  • Heather J. Landau

  • Oscar B. Lahoud

  • Michael Scordo

  • Gunjan L. Shah

  • Hani Hassoun

  • Kylee Maclachlan

  • Neha Korde

  • Urvi A. Shah

  • Carlyn Rose Tan

  • Malin Hultcrantz

  • Sergio A. Giralt

  • Saad Z. Usmani

  • Zainab Shahid

  • Sham Mailankody

  • Alexander M. Lesokhin

  • May 31, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #4

    University of Pennsylvania Abramson Cancer Center
    University of Pennsylvania Abramson Cancer Center

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

Original Source(s)

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

  • by Karthik Nath, Tala Shekarkhand, David Nemirovsky, Andriy Derkach, Bruno Almeida Costa, Noriko Nishimura, Tasmin Farzana, Colin Rueda, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee Maclachlan, Neha Korde, Urvi A. Shah, Carlyn Rose Tan, Malin Hultcrantz, Sergio A. Giralt, Saad Z. Usmani, Zainab Shahid, Sham Mailankody, Alexander M. Lesokhin

  • May 31, 2024

Related Content

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

Not all plasma cells are made equal: well-hidden layers of heterogeneity